Replies to post #241887 on Biotech Values

[DewDiligence]

CYTK reports detailed phase-2 data for CK-274—a potential competitor to BMY’s Mavacamten in obstructive HCM:

https://www.globenewswire.com/news-release/2022/04/02/2415168/35409/en/Cytokinetics-Announces-Results-From-Cohort-3-of-Redwood-HCM-Presented-at-American-College-of-Cardiology-71st-Annual-Scientific-Session.html

See #msg-167227908 for related (albeit somewhat stale) discussion.